Cat. No. 1759
Alternative Name: RU 23908
Chemical Name: 5,5-Dimethyl-3-[4-nitro-3-(trifluor
Biological ActivityNon-steroidal and silent antiandrogen. Binds to androgen receptors and also inhibits androgen biosynthesis in vitro. In rats in vivo it inhibits androgen-induced prostate weight increase and inhibits negative androgen-dependent gonadotropin feedback leading to an increase in luteinising hormone and testosterone. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Ayub and Levell (1987) Inhibition of rat testicular 17-α-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro. J.Steroid Biochem. 28 43. PMID: 2956461.
Raynaud et al (1985) Pharmacology and clinical studies with RU 23908 (Anandron). Prog.Clin.Biol.Res. 185A 99. PMID: 4034583.
Raynaud et al (1984) The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer. The Prostate 5 299. PMID: 6374639.
Raynaud et al (1979) Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues. J.Steroid Biochem. 11 93. PMID: 385986.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Nilutamide from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Nilutamide, supplier, Androgen, receptor, antagonists, Orally, active, Dihydrotestosterone, Receptors, RU23908, chemotherapeutics, Tocris Bioscience, Androgen Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Synthetic retinoid; induces differentiation of stem cellsSI-2 hydrochloride
Steroid receptor coactivator 3 (SRC-3) inhibitorSR 0987
T cell-specific RORγ (RORγt) agonistWAY 252623
Potent LXR agonist
April 1 - 5, 2017
Washington, D.C., USA